Does Private Equity backing make a research site worse?
The Association for Multisite Research Corporations (AMRC) appreciates the opportunity to provide comments regarding FDA’s proposed Expedited Investigational New Drug (IND) Pilot Program. AMRC represents a nationwide network of leading clinical research organizations conducting research across a broad range of therapeutic areas and patient populations. Our members collectively operate 466 research sites across seven countries and engage millions of patients throughout the United States.
How MCRC’s improve clinical research for the patient, Sponsor, and investor: is private equity a threat to quality?
In this spirited roundtable discussion, leading clinical trial experts will debate how PE’s impact quality at sites.
Your Sites Have Game-Changing Data (And You’re Not Asking for It)
Working hard, head down and concentrating on facing the next task or challenge, it can sometimes be easy to forget how important clinical trials are in the big picture of human health and their positive impact on alleviating suffering and prolonging the quality of life.
Your trials are leaking money, and your sites know where
Join us for an in-depth conversation on effective strategies for growing your site within today’s evolving clinical research landscape. Hear from subject matter experts representing 3 leading site networks as they share proven approaches to expanding site business by leveraging multi-site network models.
The Network Advantage: three Models, one Goal: scaling site success
Join us for an in-depth conversation on effective strategies for growing your site within today’s evolving clinical research landscape. Hear from subject matter experts representing 3 leading site networks as they share proven approaches to expanding site business by leveraging multi-site network models.
The Network Advantage: defining and recognizing quality in clinical research
Join us as we present the findings of AMRC’s 2025 industry consultation on quality in clinical research and outline the steps the association will take to define and recognise quality in practice.
The Network Advantage: We can define speed but why can’t we define quality in clinical research?
Join the Association of Multisite Research Corporations (AMRC) for an exclusive webinar unpacking the key findings from our latest whitepaper and industry consultation on quality in multisite clinical research.
The Network Advantage: A Regulatory Perspective on Clinical Research Innovation with the FDA’s David Burrow
While he’s a firm believer in the entire clinical trial process, for Carlos Orantes, Chief Executive Officer at Alcanza Clinical Research, there’s an unmistakable ‘magic’ to be found in late-stage trials. “You’re that much closer to bringing lifesaving and enhancing drugs and devices to patients by collaborating with other dedicated professionals,” he says.
The Network Advantage: A Regulatory Perspective on Clinical Research Innovation
In this informative session, clinical trial professionals will have an opportunity to hear directly from the FDA’s David Burrow on ways industry can advance clinical trial innovation.
“We’re Not Giving Up Control, We’re Just Sharing it” Highlights from AMRC’s Latest Webinar on Sponsor Pain Points
The Association of Multisite Research Corporations (AMRC), the leading trade association representing multisite clinical research corporations (MCRCs), announces Jennifer Byrne, CEO of Javara, as its newest member of the Board of Directors.
